Skip to main content
Top
Published in: BMC Infectious Diseases 1/2021

Open Access 01-12-2021 | Septic Shock | Research article

Cytokine measurements add value to clinical variables in predicting outcomes for Staphylococcus aureus bacteremia

Authors: Karen Tan, Emi Minejima, Mimi Lou, Wendy J. Mack, Paul Nieberg, Annie Wong-Beringer

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

We demonstrated that an early dysregulated cytokine response [high interleukin-10 to tissue necrosis factor (IL-10/TNF) ratio] predicted poor outcomes in patients with Staphylococcus aureus bacteremia (SAB). However, high interpatient variability in cytokine levels were observed. We grouped cytokine measurements in quartiles and assessed their additive value to clinical variables for predicting bacterial persistence and 30-day mortality in patients with SAB.

Methods

A multicenter observational study was conducted in hospitalized patients with SAB. Medical charts were reviewed for relevant information. Blood samples were obtained for cytokine measurements by ELISA: interferon-gamma (IFNγ), interleukin (IL-1β, IL-6, IL-8, IL-10, IL-17) and tissue necrosis factor (TNF). Cytokine measurements were grouped into quartiles. Significant predictors for bacterial persistence and 30-day mortality were determined by multivariable logistic regression analysis. Area under the ROC curve (AUC) analysis was performed and predictive performance was compared between models with and without cytokine quartiles.

Results

Among 606 patients with SAB, a subset of patients (n = 239) had Day 1 cytokine measurements and clinical data collected; of those, 53 (22%) had persistent bacteremia. Accounting for septic shock, the addition of either IL-10 (AUC 0.708) or TNF (AUC 0.714) quartiles measured on Day 1 improved model performance for predicting bacterial persistence. All patients had Day 4 cytokine measurements; 52 patients (8.5%) died within 30-days of SAB onset. Inclusion of either IL-10 (AUC 0.873) or TNF (AUC 0.879) quartiles, but not both, measured on Day 4 to the significant clinical predictors (coronary artery disease, Pitt bacteremia score ≥ 4, and septic shock) improved model performance for mortality.

Conclusions

IL-10 or TNF levels falling within the range in the upper quartiles, when combined with clinical variables, improved model performance for predicting outcomes, and may potentially be used to support aggressive management and biomarker-guided studies to evaluate the benefit of adjunctive immunotherapy for SAB in the future.
Appendix
Available only for authorised users
Literature
3.
go back to reference Chong YP, Park SJ, Kim HS, Kim ES, Kim MN, Park KH, et al. Persistent Staphylococcus aureus bacteremia: a prospective analysis of risk factors, outcomes, and microbiologic and genotypic characteristics of isolates. Medicine (Baltimore). 2013;92(2):98–108. https://doi.org/10.1097/MD.0b013e318289ff1e. Chong YP, Park SJ, Kim HS, Kim ES, Kim MN, Park KH, et al. Persistent Staphylococcus aureus bacteremia: a prospective analysis of risk factors, outcomes, and microbiologic and genotypic characteristics of isolates. Medicine (Baltimore). 2013;92(2):98–108. https://​doi.​org/​10.​1097/​MD.​0b013e318289ff1e​.
4.
go back to reference Volk CF, Burgdorf S, Edwardson G, Nizet V, Sakoulas G, Rose WE. IL-1β and IL-10 host responses in patients with Staphylococcus aureus bacteremia determined by antimicrobial therapy. Clin Infect Dis. 2020;70(12):2634–40. https://doi.org/10.1093/cid/ciz686. Volk CF, Burgdorf S, Edwardson G, Nizet V, Sakoulas G, Rose WE. IL-1β and IL-10 host responses in patients with Staphylococcus aureus bacteremia determined by antimicrobial therapy. Clin Infect Dis. 2020;70(12):2634–40. https://​doi.​org/​10.​1093/​cid/​ciz686.
8.
go back to reference Salas DE, Minejima E, Wu J, Fang C, Wang J, She R, Nieberg P, Wong-Beringer A. Staphylococcus aureus Bacteremia in patients not meeting sepsis criteria: clinical features, host immune response and outcomes. J Clin Med Ther. 2017;2(4):27. Salas DE, Minejima E, Wu J, Fang C, Wang J, She R, Nieberg P, Wong-Beringer A. Staphylococcus aureus Bacteremia in patients not meeting sepsis criteria: clinical features, host immune response and outcomes. J Clin Med Ther. 2017;2(4):27.
11.
18.
go back to reference Tran KN, Rybak MJ. β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA. Antimicrob Agents Chemother. 2018;62(6):e00157–18. https://doi.org/10.1128/AAC.00157-18. Tran KN, Rybak MJ. β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA. Antimicrob Agents Chemother. 2018;62(6):e00157–18. https://​doi.​org/​10.​1128/​AAC.​00157-18.
20.
go back to reference Casapao AM, Jacobs DM, Bowers DR, Beyda ND, Dilworth TJ, Group R-IS. Early Administration of Adjuvant beta-lactam therapy in combination with Vancomycin among patients with methicillin-resistant Staphylococcus aureus bloodstream infection: a retrospective, Multicenter Analysis. Pharmacotherapy. 2017;37(11):1347–56. https://doi.org/10.1002/phar.2034.CrossRefPubMed Casapao AM, Jacobs DM, Bowers DR, Beyda ND, Dilworth TJ, Group R-IS. Early Administration of Adjuvant beta-lactam therapy in combination with Vancomycin among patients with methicillin-resistant Staphylococcus aureus bloodstream infection: a retrospective, Multicenter Analysis. Pharmacotherapy. 2017;37(11):1347–56. https://​doi.​org/​10.​1002/​phar.​2034.CrossRefPubMed
21.
go back to reference Dilworth TJ, Casapao AM, Ibrahim OM, Jacobs DM, Bowers DR, Beyda ND, Mercier RC. Adjuvant β-Lactam Therapy Combined with Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: Does β-Lactam Class Matter? Antimicrob Agents Chemother. 2019;63(3):e02211–18. https://doi.org/10.1128/AAC.02211-18. Dilworth TJ, Casapao AM, Ibrahim OM, Jacobs DM, Bowers DR, Beyda ND, Mercier RC. Adjuvant β-Lactam Therapy Combined with Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: Does β-Lactam Class Matter? Antimicrob Agents Chemother. 2019;63(3):e02211–18. https://​doi.​org/​10.​1128/​AAC.​02211-18.
22.
go back to reference Davis JS, Sud A, O'Sullivan MVN, Robinson JO, Ferguson PE, Foo H, et al. Combination of Vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis. 2016;62(2):173–80. https://doi.org/10.1093/cid/civ808. Davis JS, Sud A, O'Sullivan MVN, Robinson JO, Ferguson PE, Foo H, et al. Combination of Vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis. 2016;62(2):173–80. https://​doi.​org/​10.​1093/​cid/​civ808.
Metadata
Title
Cytokine measurements add value to clinical variables in predicting outcomes for Staphylococcus aureus bacteremia
Authors
Karen Tan
Emi Minejima
Mimi Lou
Wendy J. Mack
Paul Nieberg
Annie Wong-Beringer
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-06010-0

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.